Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Reck

Showing results (101-110 of 437) with videos related to

Pageof 44
Sort By:
Lung Cancer (Amsterdam, Netherlands)|March 29, 2011
Second-line erlotinib in patients with advanced non-small-cell lung cancer: subgroup analyses from the TRUST studyDavid F Heigener, Yi-Long Wu, Nico van Zandwijk, et al.
Nature Reviews. Clinical Oncology|August 15, 2025
Treatment of NSCLC after chemoimmunotherapy - are we making headway?Martin Reck, Nikolaj Frost, Solange Peters, et al.
Future Oncology (London, England)|December 6, 2014
Nintedanib plus docetaxel as second-line therapy in patients with non-small-cell lung cancer: a network meta-analysisSanjay Popat, Anders Mellemgaard, Kyle Fahrbach, et al.
Oncotargets and Therapy|August 21, 2018
Change in non-small-cell lung cancer tumor size in patients treated with nintedanib plus docetaxel: analyses from the Phase III LUME-Lung 1 studyMartin Reck, Anders Mellemgaard, Silvia Novello, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 27, 2022
Lung Cancer in GermanyNikolaj Frost, Frank Griesinger, Hans Hoffmann, et al.
Plos One|October 17, 2023
Safety and tolerability of weekly docetaxel plus nintedanib: A phase I trial after first-line chemotherapy failure in NSCLCVirginie Westeel, Wolfgang Schuette, Thierry Urban, et al.
Lung Cancer (Amsterdam, Netherlands)|May 11, 2020
Anti-angiogenic agents in the age of resistance to immune checkpoint inhibitors: Do they have a role in non-oncogene-addicted non-small cell lung cancer?Sanjay Popat, Christian Grohé, Jesus Corral, et al.
Cancer Treatment Reviews|August 21, 2018
Patient-reported outcomes with nivolumab in advanced solid cancersScott S Tykodi, Dirk Schadendorf, David Cella, et al.
Future Oncology (London, England)|December 13, 2025
Frontline sigvotatug vedotin plus pembrolizumab vs pembrolizumab for non-small cell lung cancer with PD-L1 tumor proportion score ≥50%: phase III study designMartin Reck, Shun Lu, Kenneth J O'Byrne, et al.
Nature Reviews. Clinical Oncology|July 1, 2026
Improving neoadjuvant and perioperative therapy in non-small-cell lung cancerYago Garitaonaindia, Heather A Wakelee, Martin Reck, et al.
Pageof 44

Showing results (101-110 of 437) with videos related to

Sort By:
Pageof 44
Lung Cancer (Amsterdam, Netherlands)|March 29, 2011
Second-line erlotinib in patients with advanced non-small-cell lung cancer: subgroup analyses from the TRUST studyDavid F Heigener, Yi-Long Wu, Nico van Zandwijk, et al.
Nature Reviews. Clinical Oncology|August 15, 2025
Treatment of NSCLC after chemoimmunotherapy - are we making headway?Martin Reck, Nikolaj Frost, Solange Peters, et al.
Future Oncology (London, England)|December 6, 2014
Nintedanib plus docetaxel as second-line therapy in patients with non-small-cell lung cancer: a network meta-analysisSanjay Popat, Anders Mellemgaard, Kyle Fahrbach, et al.
Oncotargets and Therapy|August 21, 2018
Change in non-small-cell lung cancer tumor size in patients treated with nintedanib plus docetaxel: analyses from the Phase III LUME-Lung 1 studyMartin Reck, Anders Mellemgaard, Silvia Novello, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 27, 2022
Lung Cancer in GermanyNikolaj Frost, Frank Griesinger, Hans Hoffmann, et al.
Plos One|October 17, 2023
Safety and tolerability of weekly docetaxel plus nintedanib: A phase I trial after first-line chemotherapy failure in NSCLCVirginie Westeel, Wolfgang Schuette, Thierry Urban, et al.
Lung Cancer (Amsterdam, Netherlands)|May 11, 2020
Anti-angiogenic agents in the age of resistance to immune checkpoint inhibitors: Do they have a role in non-oncogene-addicted non-small cell lung cancer?Sanjay Popat, Christian Grohé, Jesus Corral, et al.
Cancer Treatment Reviews|August 21, 2018
Patient-reported outcomes with nivolumab in advanced solid cancersScott S Tykodi, Dirk Schadendorf, David Cella, et al.
Future Oncology (London, England)|December 13, 2025
Frontline sigvotatug vedotin plus pembrolizumab vs pembrolizumab for non-small cell lung cancer with PD-L1 tumor proportion score ≥50%: phase III study designMartin Reck, Shun Lu, Kenneth J O'Byrne, et al.
Nature Reviews. Clinical Oncology|July 1, 2026
Improving neoadjuvant and perioperative therapy in non-small-cell lung cancerYago Garitaonaindia, Heather A Wakelee, Martin Reck, et al.
Pageof 44